These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 32843477)

  • 41. Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Treatment of Chronic Hepatitis C: A Prospective Cohort Study in Portugal.
    Vera J; Gomes A; Póvoas D; Seixas D; Maltez F; Pedroto I; Maia L; Mota M; Vieira MJ; Manata MJ; Ferreira P; Lino S; Pereira Guedes T; Barradas V; Marques N
    Acta Med Port; 2024 May; 37(5):323-333. PubMed ID: 38325411
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcomes of Kidneys Transplanted From Hepatitis C Viremic Donors to Naive Recipients From an Appalachian Rural Kidney Transplant Program.
    Gillis B; Villanueva D; Marsh W; Afridi F; Danforth J; Thornberg M; Chaudhary V; Sharma R
    Exp Clin Transplant; 2024 Mar; 22(3):185-188. PubMed ID: 38695587
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Glecaprevir/pibrentasvir in combination with ribavirin as salvage therapy in chronic hepatitis C].
    Sánchez Suárez MM; Martín Roldán A; Cantudo Cuenca MR
    Rev Esp Quimioter; 2024 Jun; 37(3):283-284. PubMed ID: 38638059
    [No Abstract]   [Full Text] [Related]  

  • 44. Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients.
    Aqel B; Wijarnpreecha K; Pungpapong S; Taner CB; Reddy K; Leise M; Mi L; Dickson RC
    J Hepatol; 2021 Apr; 74(4):873-880. PubMed ID: 33188903
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study.
    Poordad F; Felizarta F; Yao BB; Overcash JS; Hassanein T; Agarwal K; Gane E; Shaw D; Waters M; Krishnan P; Topp A; Burroughs M; Nevens F
    Liver Int; 2022 Jun; 42(6):1278-1286. PubMed ID: 35220658
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 'Real-life' experience with direct-acting antiviral agents for HCV after kidney transplant.
    Fabrizi F; Alonso C; Palazzo A; Anders M; Reggiardo MV; Cheinquer H; Zuain MGV; Figueroa S; Mendizabal M; Silva M; Ridruejo E;
    Ann Hepatol; 2021; 25():100337. PubMed ID: 33684523
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.
    Forns X; Lee SS; Valdes J; Lens S; Ghalib R; Aguilar H; Felizarta F; Hassanein T; Hinrichsen H; Rincon D; Morillas R; Zeuzem S; Horsmans Y; Nelson DR; Yu Y; Krishnan P; Lin CW; Kort JJ; Mensa FJ
    Lancet Infect Dis; 2017 Oct; 17(10):1062-1068. PubMed ID: 28818546
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies.
    Yao BB; Fredrick LM; Schnell G; Kowdley KV; Kwo PY; Poordad F; Nguyen K; Lee SS; George C; Wong F; Gane E; Abergel A; Spearman CW; Nguyen T; Hung Le M; Pham TT; Mensa F; Asselah T
    Liver Int; 2020 Oct; 40(10):2385-2393. PubMed ID: 32445613
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis.
    Back D; Belperio P; Bondin M; Negro F; Talal AH; Park C; Zhang Z; Pinsky B; Crown E; Mensa FJ; Marra F
    J Viral Hepat; 2019 Aug; 26(8):951-960. PubMed ID: 30977945
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
    Kwo PY; Poordad F; Asatryan A; Wang S; Wyles DL; Hassanein T; Felizarta F; Sulkowski MS; Gane E; Maliakkal B; Overcash JS; Gordon SC; Muir AJ; Aguilar H; Agarwal K; Dore GJ; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
    J Hepatol; 2017 Aug; 67(2):263-271. PubMed ID: 28412293
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of glecaprevir/pibrentasvir on weight-adjusted tacrolimus trough/dose ratios in heart and kidney transplant recipients.
    Nnani DU; Campbell A; Ajaimy M; Saeed O; Patel SR; Ahmed S; Graham JA; Jorde UP
    Transpl Infect Dis; 2021 Oct; 23(5):e13716. PubMed ID: 34407270
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience.
    Ueda Y; Kobayashi T; Ikegami T; Miuma S; Mizuno S; Akamatsu N; Takaki A; Ishigami M; Takatsuki M; Sugawara Y; Maehara Y; Uemoto S; Seno H
    J Gastroenterol; 2019 Jul; 54(7):660-666. PubMed ID: 30806783
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
    Ng TI; Pilot-Matias T; Tripathi R; Schnell G; Krishnan P; Reisch T; Beyer J; Dekhtyar T; Irvin M; Lu L; Asatryan A; Campbell A; Yao B; Lovell S; Mensa F; Lawitz EJ; Kort J; Collins C
    Viruses; 2018 Aug; 10(9):. PubMed ID: 30154359
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
    Umemura M; Suda G; Tsukamoto S; Ebata K; Takahash S; Sasaki T; Nakajima S; Hirata K; Ozasa M; Takano M; Katagiri M; Sakamoto N
    BMC Infect Dis; 2021 Apr; 21(1):389. PubMed ID: 33906643
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study.
    Rockstroh JK; Lacombe K; Viani RM; Orkin C; Wyles D; Luetkemeyer AF; Soto-Malave R; Flisiak R; Bhagani S; Sherman KE; Shimonova T; Ruane P; Sasadeusz J; Slim J; Zhang Z; Samanta S; Ng TI; Gulati A; Kosloski MP; Shulman NS; Trinh R; Sulkowski M
    Clin Infect Dis; 2018 Sep; 67(7):1010-1017. PubMed ID: 29566246
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials.
    Heo J; Kim YJ; Lee JW; Kim JH; Lim YS; Han KH; Jeong SH; Cho M; Yoon KT; Bae SH; Crown ED; Fredrick LM; Alami NN; Asatryan A; Kim DH; Paik SW; Lee YJ
    Gut Liver; 2021 Nov; 15(6):895-903. PubMed ID: 34053916
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection.
    Suda G; Hasebe C; Abe M; Kurosaki M; Itakura J; Izumi N; Uchida Y; Mochida S; Haga H; Ueno Y; Abe K; Takahashi A; Ohira H; Tsukuda Y; Furuya K; Baba M; Yamamoto Y; Kobayashi T; Inoue J; Terasita K; Ohara M; Kawagishi N; Izumi T; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N;
    J Gastroenterol; 2019 Jul; 54(7):641-649. PubMed ID: 30778716
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients.
    Eckman MH; Woodle ES; Thakar CV; Alloway RR; Sherman KE
    Am J Kidney Dis; 2020 Jun; 75(6):857-867. PubMed ID: 32081494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use: Some issues.
    Dai CY; Huang CF; Huang JF; Chuang WL; Yu ML
    J Infect; 2022 Oct; 85(4):e94-e95. PubMed ID: 35810942
    [No Abstract]   [Full Text] [Related]  

  • 60. Successful nasoenteric administration of glecaprevir/pibrentasvir for donor-derived hepatitis C in two young adult heart transplant recipients at a pediatric transplant center.
    Kushner LE; Puckett L; Lee J; Joerger T; Chen SF; Profita E
    Pediatr Transplant; 2022 Nov; 26(7):e14360. PubMed ID: 35854405
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.